What Longevity Vision Fund does

Longevity Vision Fund (legal entity: Longevity Vision Holding) is a New York-based venture capital firm founded in 2018 and launched in 2019 by Sergey Young with approximately $100 million in capital. The fund invests exclusively in companies developing technologies intended to extend healthy human lifespan, with stated focus areas including AI-driven drug discovery, diagnostics, regenerative medicine, CRISPR-based therapies, senolytics, epigenetic reprogramming, and longevity-focused health monitoring.

The fund's portfolio of nearly twenty companies is concentrated in early-to-mid-stage biotechnology and digital health. Visible holdings span gene writing and gene therapy (Tessera Therapeutics, 4DMT, Sigilon, Laronde), AI-native drug discovery (Insilico Medicine, Valo Health), early cancer and disease diagnostics (Freenome), organ regeneration (LyGenesis — which raised a $100M Series B), exosome-based therapeutics (exo), programmable medicines (Senda), and biosensors and digital health (Biolinq, eko, Fountain Life). The fund's stated investment thesis is that converging forces — analogous to early personal computing — are creating a new longevity industry.

The business model is conventional venture capital: equity investments in longevity-focused startups, with returns generated through portfolio company exits via IPO or acquisition. Sergey Young provides top-of-funnel credibility through his board seat at the American Federation for Aging Research, support for Healthspan XPRIZE, and authorship of a bestselling book on longevity. The firm has received Fast Company's "World Changing Ideas" recognition. Operating geographies, institutional LP composition, and detailed fund economics are not publicly disclosed.

Name

Longevity Vision Fund

Legal name

Longevity Vision Holding

Website

https://lvf.vc

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Longevity Vision Fund is a New York-based venture capital firm investing in longevity and anti-aging biotechnology startups. Deploying approximately $100 million across nearly twenty portfolio companies spanning AI-driven drug discovery, diagnostics, gene therapy, and regenerative medicine.

Ownership category

akta.pro rank

Product category

Venture Capital

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

SDG / Thematic Sustainable Investment Funds (FSANAJAN)

akta.pro secondary industry

Impact Investment & Development Investment Funds (BPADACAO)

Keywords

• Venture capital funding
• Longevity biotechnology
• Life sciences investment
• Biotech portfolio management
• Anti-aging startups

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Returns: Longevity Vision Fund generates returns through equity investments in longevity-focused startups. The fund was launched with approximately $100 million in capital to deploy across portfolio companies, seeking capital appreciation through exits via IPOs or acquisitions in the longevity biotechnology sector.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Longevity Vision Fund is a venture capital fund launched in 2019 by Sergey Young with approximately $100 million in capital to deploy as equity investments in early to mid-stage longevity and anti-aging biotechnology startups. The fund backs companies across healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine, seeking capital appreciation through IPO or acquisition exits.

Product overview

Longevity Vision Fund is a venture capital fund that invests in longevity and anti-aging biotechnology companies. The fund was launched in 2019 with approximately $100 million and has built a portfolio of nearly twenty companies focused on healthy aging, AI-driven drug discovery, diagnostics, and regenerative medicine. The portfolio companies include Freenome, Insilico Medicine, Tessera Therapeutics, LyGenesis, and others spanning areas such as epigenetic reprogramming, senolytics, regenerative medicine, and longevity diagnostics. The fund's portfolio page lists 13 portfolio companies including 4DMT, Tessera Therapeutics, EKO, EXO, Sigilon, Insilico Medicine, Freenome, Valo, Senda, Biolinq, LyGenesis, and Laronde.

Differentiator

Problem solved

Functional benefit

Products and services

• Longevity Vision Fund A venture capital fund with approximately $100 million of deployable capital that makes equity investments in longevity and anti-aging biotechnology companies. The fund targets early to mid-stage startups developing healthy aging interventions, AI-driven drug discovery, diagnostics, senolytics, regenerative medicine, and longevity-related therapeutics.

Quantifiable outcome

• Portfolio company LyGenesis raised $100 million Series B
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• American Federation for Aging ResearchcoreStrategic or Co-development Partner · 1 January 2019Sergey Young, founder of Longevity Vision Fund, serves on the board of the American Federation for Aging Research, providing strategic alignment and credibility in the longevity investment space.
• Healthspan XPRIZEcoreStrategic or Co-development PartnerLongevity Vision Fund supports Healthspan XPRIZE, a major initiative to accelerate development of interventions that extend healthy human lifespan.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Founders Fund: Peter Thiel-led VC firm with publicly stated interest in longevity and anti-aging. Invests across biotech and technology with overlap on longevity-themed portfolio companies.
• Khosla Ventures: Large diversified VC firm with significant biotech and longevity investments. Co-invests in many of the same companies (e.g., Insilico Medicine) but operates across multiple sectors beyond longevity.
• Andreessen Horowitz (a16z Bio): Major VC firm with a dedicated bio/health fund investing in biotech, digital health, and longevity-adjacent companies. Well-capitalized incumbent competing for the same thesis at scale.
• Y Combinator: Accelerator with an active longevity and biotech track record. Funds very early-stage longevity startups that may later become Longevity Vision Fund portfolio candidates.

Emerging players

• Civilization Ventures: Early-stage VC fund focused on healthspan and longevity. Similar thematic focus but smaller and earlier-stage than Longevity Vision Fund, with potentially overlapping deal flow.

Direct peers

• Bold Capital Partners: Thematic venture firm investing in longevity, biotech, and exponential technologies. Overlapping focus areas, target companies, and LP audience make it a close peer.
• Apollo Ventures: Venture capital fund focused on aging biology and longevity therapeutics. Competes directly with Longevity Vision Fund for investment opportunities in age-reversal and healthspan companies.
• LongeVC: Early-stage venture capital fund dedicated exclusively to longevity and healthspan biotech. Direct competitor for the same longevity-focused founders, investment themes, and LP base as Longevity Vision Fund.
• Healthspan Capital: Dedicated longevity-focused investment firm. Comparable thesis on healthspan extension and overlapping investment universe in aging therapeutics.
• The Longevity Fund: Early-stage VC fund focused on extending healthy human lifespan. Direct thematic peer competing for similar deal flow in the longevity biotech category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Longevity Vision Fund